Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

SMP-534

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Recent insights into diabetic renal injury from the db/db mouse model of type 2 diabetic nephropathy.
  • G. Tesch, A. Lim
  • American journal of physiology. Renal physiology
  • 2011
    • Corpus ID: 2896558
The db/db mouse is the most widely used animal model of type 2 diabetic nephropathy. Recent studies have utilized genetic… Expand
  • figure 1
  • table 1
  • table 2
2009
2009
Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats.
The number of patients with chronic kidney disease (CKD) has continuously grown worldwide. Treatment with antihypertensive agents… Expand
  • figure 3
  • figure 1
  • figure 2
  • figure 4
  • figure 5
2009
2009
The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters.
Pulmonary fibrosis is a progressive and lethal lung disease characterized by accumulation of ECM and loss of pulmonary function… Expand
2008
2008
Chronic Administration of SMP-534 Ameliorates Renal Dysfunction in 5/6 Nephrectomized Rats
Background/Aims: Chronic kidney disease (CKD) is the common cause of end-stage renal disease. Antihypertensive agents are… Expand
  • figure 1
  • figure 4
  • figure 5
  • figure 6
  • figure 7
2006
2006
SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Diabetic nephropathy is currently the most common cause of end-stage renal disease. Diabetic nephropathy patients, whether… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2006
2006
Enhanced Effect of Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in Diabetic Nephropathy
Background/Aims: Diabetic nephropathy is now the most common cause of end-stage renal disease. It is also clear that the current… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2006
2006
Amelioration of Established Diabetic Nephropathy by Combined Treatment with SMP-534 (Antifibrotic Agent) and Losartan in db/db Mice
Background/Aims: Diabetic nephropathy is the main cause of end-stage renal disease. Previously we have demonstrated that SMP-534… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2006
2006
Study of pharmacological action of SMP-534, a novel anti-fibrotic agent, in diabetic nephropathy
 
2006
2006
Study of pharmacological action of SMP-534, a novel anti-fibrotic agent, in diabetic nephropathy
 
2005
2005
SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis.
Transforming growth factor-beta (TGF-beta) is a potent fibrotic factor responsible for the synthesis of extracellular matrix (ECM… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE